# Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

> **NCT06413992** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 117 (estimated)

## Conditions studied

- Endometrial Carcinoma
- TP53 Mutation
- Recurrent or Metastatic

## Interventions

- **DRUG:** Fluzoparib
- **DRUG:** Camrelizumab
- **DRUG:** paclitaxel (albumin bound)
- **DRUG:** Carboplatin injection
- **DRUG:** Carboplatin
- **RADIATION:** External irradiation

## Key facts

- **NCT ID:** NCT06413992
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-10
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413992, "Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06413992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*